Women who have acne along their jawline and lower face tend to have good results from hormonal therapy for acne.
Do you continue to see acne along your lower face, jawline, and neck despite trying all sorts of acne treatments? Have you taken an antibiotic to treat your acne and been disappointed with the results? Are you struggling to clear acne on your chest or back as well?
Women who answer yes to any of these questions may want to consider hormonal therapy for acne.
Any medication that acts on our hormones is called hormonal therapy. Two hormonal therapies that can effectively clear acne in women are:
The pill: Many studies have looked at how well oral contraceptive pills fight acne. The pill has been found effective at treating blackheads, whiteheads, pimples, and acne nodules and cysts.
In fact, the pill has proven so effective that the U.S. Food and Drug Administration (FDA) has approved some oral contraceptives for treating acne.
The pill is generally considered safe for women. Some women, however, should not take it. Your dermatologist can tell you whether the pill may be a safe and effective treatment option for you.
Spironolactone: Doctors prescribe this medication to treat high blood pressure. It’s also prescribed for people who are retaining too much fluid.
Dermatologists have been prescribing it for many years to treat acne and excess hair growth in women. When other acne treatments don’t work, it can effectively treat deep-seated, tender acne on the lower face, jawline, or neck.
Spironolactone is not prescribed to treat acne in men due to side effects. Men have developed breasts while taking this medication to treat acne.
Spironolactone is generally considered safe for healthy women.
Taking both spironolactone and the pill can increase effectiveness. This combination has another advantage. It’s essential to use birth control while taking spironolactone. If you get pregnant while taking spironolactone, your baby can have serious birth defects.
Spironolactone may also be prescribed without the pill. If you’re 35 years of age or older, the pill may not be an option for you and only spironolactone may be prescribed. Taking spironolactone without the pill is also recommended when you have a medical condition that makes it unsafe to take the pill, such as having had a blood clot or stroke.
A word of caution: If you can get pregnant, you’ll need to use birth control while taking spironolactone.
When taken alone, spironolactone can be quite effective. In looking at the medical records of 85 women who took spironolactone, researchers found that 1/3 of the women had complete clearing and 1/3 had noticeably less acne. Only 7% saw no improvement.
Studies have also shown spironolactone to be effective. Improvement ranges from a 50% to 100% reduction in acne.
Before taking spironolactone, it’s important to know that this medication is a diuretic, so you’ll find yourself urinating more often. If this could be a problem, let your dermatologist know.
Taking spironolactone? Too much potassium can be dangerous. Skip the coconut water and supplements that contain potassium.
These medications must be prescribed by a doctor. Each is a pill that you would take daily.
If you’re wondering whether hormonal therapy could help clear your acne, you may want to make an appointment to see a dermatologist. After examining your acne and gathering the necessary information about your health, this doctor can tell you if hormonal therapy may be an option.
Before you see a dermatologist, it helps to prepare for your appointment. You’ll want to be able to tell your dermatologist the following:
If the pill is an option for you, you will have your blood pressure taken to rule out high blood pressure. You don’t need a Pap smear or pelvic exam before a dermatologist can prescribe the pill to treat acne.
Before your dermatologist prescribes spironolactone, you will need some blood tests.
If you begin hormonal therapy, you will need to keep follow-up visits with your dermatologist. Spironolactone requires that you gradually increase the dose, so you’ll need to see your dermatologist every 4 to 6 weeks when you start taking it.
|Hormonal therapy||Time to see results|
|The pill||2 to 3 months|
|Spironolactone||Most patients notice a decrease in breakouts and oiliness in a few weeks.|
When hormonal therapy helps to clear acne, a patient may stay on it for a long time. You will often stop other acne treatments like an antibiotic and medication that you apply to your skin. Hormonal therapy can be used alone to prevent new breakouts.
Taking hormonal therapy long term appears to be safe.
Taking spironolactone to keep your skin clear? Studies show taking it at the same time every day can give you the best results.
To reduce the risk of a woman developing serious side effects, dermatologists carefully screen their patients before prescribing hormonal therapy. Possible side effects include the following:
The pill: Taking the pill increases the risk of:
While these side effects may not seem worth the risk, most women who are healthy do not have side effects. In fact, the risk of developing blood clots is greater during pregnancy and just after having a baby than when taking the pill.
It’s also important to know that there is less risk of serious side effects today than in past. Today, the pill contains less estrogen.
Some women taking the pill develop melasma, dark patches on their face. Protecting your face from the sun can help prevent these patches.
Breakthrough bleeding is another possible side effect. You can often prevent this by taking the pill at the same time each day.
Taking the pill? Stay active, drink lots of water, and don’t smoke. This reduces the risk of blood clots.
Spironolactone: When taking spironolactone without a birth control pill, the most common side effects are:
These side effects may be decreased when women also take the pill.
Other possible side effects of taking spironolactone include fatigue, headache, and dizziness. These rarely cause a woman to stop taking the medication.
You may also see a warning about breast cancer in the information that comes with the medication. This warning was included after researchers gave animals very high doses of spironolactone. Some of the animals developed breast cancer.
The possibility that this medication increases a woman’s risk of getting breast cancer is still controversial.
We really don’t have evidence that shows taking spironolactone increases the risk of getting breast cancer. In one study, 1,475 patients prescribed spironolactone were followed for 3 to 7 years. During that time, 9 cases of breast cancer were reported. If none of these patients had taken spironolactone, it is expected that about 8 of them would have developed breast cancer during that time. Other studies have shown similar results.
When taking hormonal therapy for acne, it’s helps to:
Hormonal therapy is an option for many women with stubborn acne, but it’s not always the only option. A dermatologist can tell you what can help clear your stubborn acne.
Images: Getty Images
Carol, R. “Hormonal therapies serve as key adjunct acne treatment.” Dermatol World. 2012 May (Acne suppl). 2-6.
Ebede TL, Arch EL, et al. “Hormonal treatment of acne in women.” J Clin Aesthet Dermatol. 2009; 2(12): 16–22.
Harper JC. “Use of oral contraceptives for management of acne vulgaris. Practical considerations in real world practice.” Dermatol Clin. 2016;34(2):159-65.
Kim GK, Del Rosso JQ. “Oral spironolactone in post-teenage female patients with acne vulgaris: Practical considerations for the clinician based on current data and clinical experience.” J Clin Aesthet Dermatol. 2012;5(3):37-50.
Plovanich M; Weng QY, et al. “Low usefulness of potassium monitoring among healthy young women taking spironolactone for acne.” JAMA Dermatol. 2015;151(9):941-4.
Reynolds RVS. ‘Hormonal treatment for acne.” Presented during the forum: Acne guidelines: Translating evidence into practice. 2017 Annual Meeting of the American Academy of Dermatology; 2017 March 3-7. Orlando, FL.
Zaenglein AL, Pathy AL et al. “Guidelines of care for the management of acne vulgaris.” J Am Acad Dermatol. 2016;74:945-73.